- Director, Hematologic Malignancies and Stem Cell Transplant Program
- Director, Bone Marrow Transplant
- Division Chief, Hematology and Oncology
Marcos de Lima, MD, is Director of the Hematologic Malignancies and Stem Cell Transplant programs at University Hospitals Cleveland Medical Center. He is also Professor of Medicine at Case Western Reserve University. Prior to joining the UH Cleveland Medical Center staff in 2012, he served as Professor of Medicine, Department of Stem Cell Transplantation and Cellular Therapy at M.D. Anderson Cancer Center in Houston, Texas.
Dr. de Lima earned his Medical Doctor and Master in Internal Medicine degrees at Federal University of Rio de Janeiro School of Medicine, Rio de Janiero, Brazil. He completed a fellowship in Medical Oncology at University of Texas, M.D Anderson Cancer Center, Houston, Texas.
A dedicated researcher, Dr. de Lima has extensive experience in developing and conducting clinical trials in the context of stem cell transplantation for cancers beginning in blood-borne tissue, bone marrow or in the cells of the immune system. His research focuses on strategies to expand transplantation of blood stem cells from one patient to another and in the treatment and prevention of post-transplant leukemia relapse.
Dr. de Lima has approximately 230 published manuscripts and has written chapters for nearly a dozen textbooks. He is currently the acute leukemia working group co-chair, Center for International Bone Marrow Transplant Research.
- Bone Marrow Transplantation
- Hematologic Malignancies
- Waun Ki Hong Award for Excellence in Team Science
- Don C. Dangler Endowed Director in Stem Cell Transplant
Fellowship | Medical Oncology
Medical Oncology - University Of Texas Md Anderson Cancer Center (1994 - 1997)
Universidade Federal Do Rio De Janeiro (1986)
Hematologic cancers and bone marrow, cord blood or peripheral blood stem cell transplant
University Hospitals is committed to transparency in our interactions with industry partners, such as pharmaceutical, biotech, or medical device companies. At UH, we disclose practitioner and their family members’ ownership and intellectual property rights that are or in the process of being commercialized. In addition, we disclose payments to employed practitioners of $5,000 or more from companies with which the practitioners interact as part of their professional activities. These practitioner-industry relationships assist in developing new drugs, devices and therapies and in providing medical education aimed at improving quality of care and enhancing clinical outcomes. At the same time, UH understands that these relationships may create a conflict of interest. In providing this information, UH desires to assist patients in talking with their practitioners about industry relationships and how those relationships may impact their medical care.
UH practitioners seek advance approval for certain new industry relationships. In addition, practitioners report their industry relationships and activities, as well as those of their immediate family members, to the UH Office of Outside Interests annually. We review these reports and implement management plans, as appropriate, to address conflicts of interest that may arise in connection with medical research, clinical care and purchasing decisions.
View UH’s policy (PDF) on practitioner-industry relationships.
As of December 31, 2016, Marcos de Lima did not disclose any Outside Relationships with Industry.